Fluoroquinolones halt multidrug-resistant-TB in contacts
Gregory J. Fox, M.D., Ph.D., from the Montreal Chest Unit in McGill University, and colleagues examined the potential benefits, risks, and cost-effectiveness of FQN therapy to prevent TB in contacts of individuals with MDR-TB. Decision analysis was used to compare costs and outcomes associated with no treatment versus a six-month daily FQN course in contacts of those with MDR-TB.
The researchers found that there were health system savings, lower incidence of MDR-TB, and lower mortality for FQN preventive therapy versus no treatment. With FQN therapy of infected contacts, the incidence of MDR-TB with acquired FQN resistance would also be lower.
"In our model, FQN preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of MDR-TB, and incidence of acquired FQN-resistant disease as well as improved quality of life," the authors write. "FQN therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing MDR-TB was as low as 10 percent."
Editorial (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.